This report shows that biopharmaceutical research companies continue to be vitally important to the economy and patient health in Connecticut, despite the recession. 

At a time when the state still faces significant economic challenges, biopharmaceutical research companies are conducting or have conducted more than 2,000 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals. Of the more than 2,000 clinical trials, 1,043 target or have targeted the nation’s six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.

“Clinical trials of new medicines are good not only for patients, but also the state’s economy. About half of those that are underway or have been conducted over the last 13 years are for such challenging diseases as asthma, heart disease, stroke, cancer, diabetes and mental illnesses. These new treatments have the potential to improve the quality of overall patient health care. Clinical trials of new drugs are also a good source of revenue for the state’s university medical schools, local hospitals and clinical research centers.” --Eric George, Connnecticut Business & Industry Association